RxDoctor Payments Data

Kelly Seals

Nurse Practitioner · Fredericksburg, TXNPI 1063855757

Payments from drug & device makers

$4,979in general payments, 2019–2025

Across 264 payments — averaging $18.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$920
  • Pfizer$421
  • Johnson & Johnson$179
  • Aimmune Therapeutics, Inc.$176
  • Sanofi$175
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$4,972100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,979 in reported general payments places this provider in the 90th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$84,030
Medicare patients
553
Services billed
937

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase59$147,070
XifaxanRifaximin47$117,172
ZenpepLipase/Protease/Amylase32$109,843
LinzessLinaclotide70$53,186
TrulancePlecanatide20$15,128
Dexlansoprazole DrDexlansoprazole30$10,998
Pantoprazole Sodium768$7,899
Budesonide DrBudesonide41$5,667
SutabSod Sulf/Pot Chloride/Mag Sulf21$3,395
DexilantDexlansoprazole11$3,324
Mesalamine ErMesalamine14$2,864
Colesevelam Hcl17$2,040
Famotidine58$1,685
Omeprazole147$1,589
Colestipol Hcl13$1,419

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,626$200,256129 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$920$132,30067 claims
Aimmune Therapeutics, Inc.Zenpep$176$109,84332 claims
Braintree Laboratories, Inc.Sutab$40$3,39521 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$78$3,32411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Fredericksburg

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →